NCT06099652View on ClinicalTrials.gov

Evaluation of 611 in Chinese Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease

PHASE2RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

December 8, 2023

Primary Completion Date

April 30, 2025

Study Completion Date

May 31, 2025

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

611 300 mg Q2W

611 subcutaneous (SC) injection

DRUG

611 450 mg Q2W

611 subcutaneous (SC) injection

DRUG

Matching placebo

placebo subcutaneous (SC) injection

Trial Locations (3)

100029

NOT_YET_RECRUITING

China-Japan Friendship Hospital, Beijing

200032

NOT_YET_RECRUITING

Zhongshan Hospital affiliated to Fudan University, Shanghai

518020

RECRUITING

Shenzhen People's Hospital, Shenzhen

All Listed Sponsors
lead

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

INDUSTRY